Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities

US8258263B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Sherie L. Morrison · Los Angeles, US
• Tzu-Hsuan Huang · Zhubei City, TW
• Caiyun Xuan · Los Angeles, US

Key dates

• Filing date: Dec 30, 2009
• Grant date: Sep 4, 2012
• Expiry date: Dec 30, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-α) or interferon beta (IFN-β).